Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer
Tatsuya Yoshida, Feifei Wei, Taku Kouro, Kosuke Kawaguchi, Tatsuki R Kataoka, Hiroyuki Yasojima, Hiroko Bando, Takashi Kuwayama, Rikiya Nakamura, Shigenori E Nagai, Norikazu Masuda, Masakazu Toi, Tetsuro Sasada · 2026
Read Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer by Tatsuya Yoshida, Feifei Wei, Taku Kouro, Kosuke Kawaguchi, Tatsuki R Kataoka, Hiroyuki Yasojima, Hiroko Bando, Takashi Kuwayama, Rikiya Nakamura, Shigenori E Nagai, Norikazu Masuda, Masakazu Toi, Tetsuro Sasada (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13195858.txt.
Description
BackgroundNeoadjuvant chemotherapy (NAC) with anti-HER2 agents is standard for HER2-positive breast cancer, achieving pathological complete response (pCR) in 40–50% of patients; however, reliable predictors of response remain limited. HER2 is an immunogenic antigen capable of eliciting humoral responses, yet the predictive value of HER2-specific autoantibodies in the neoadjuvant setting remains unclear.
Catalog record
| CREATOR | Tatsuya Yoshida, Feifei Wei, Taku Kouro, Kosuke Kawaguchi, Tatsuki R Kataoka, Hiroyuki Yasojima, Hiroko Bando, Takashi Kuwayama, Rikiya Nakamura, Shigenori E Nagai, Norikazu Masuda, Masakazu Toi, Tetsuro Sasada |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer Authors: Tatsuya Yoshida, Feifei Wei, Taku Kouro, Kosuke Kawaguchi, Tatsuki R Kataoka, Hiroyuki Yasojima, Hiroko Bando, Takashi Kuwayama, Rikiya Nakamura, Shigenori E Nagai, Norikazu Masuda, Masakazu Toi, Tetsuro Sasada Published: 2026 ABSTRACT AbstractBackgroundNeoadjuvant chemotherapy (NAC) with anti-HER2 agents is standard for HER2-positive breast cancer, achieving pathological complete response (pCR) in 40–50% of patients; however, reliable predictors of response remain limited. HER2 is an immunogenic antigen capable of eliciting humoral responses, yet the predictive value of HER2-specific autoantibodies in the neoadjuvant setting remains unclear. We investigated whether HER2-peptide–specific antibody responses could serve as potential biomarkers of treatment response.MethodsPaired pre- and post-NAC sera from 112 patients enrolled in the JBCRG-16 (Neo-Lath) trial, which evaluated trastuzumab- and lapatinib-containing NAC, were analyzed. IgG titers against 63 non-overlapping 20-mer HER2-derived peptides were measured using a multiplex bead array, and serum HER2 protein levels were also quantified. Data were analyzed using Wilcoxon signed-rank and rank-sum tests, Spearman’s correlation analyses, and univariate logistic regression for pCR. Predictive models were constructed using elastic net regression with nested cross-validation across pretreatment, posttreatment, and fold-change datasets, and model performance was assessed by the area under the receiver operating characteristic curve (AUC).ResultsHER2-derived peptides elicited heterogeneous immune responses, and IgG titers against 37 of 63 peptides (58.7%) significantly decreased after NAC. Pretreatment IgG titers were positively correlated with the Boman index and negatively correlated with the aliphatic index. In univariate analyses, neither IgG titers nor serum HER2 levels at either time point, nor their treatment-induced changes, were significantly associated with pCR. In contrast, a predictive model based on treatment-induced changes in a subset of peptide-specific IgG titers demonstrated consistent predictive performance (AUC 0.78 in training and 0.79 in validation). Six peptides distributed across the HER2 sequence contributed to pCR prediction.ConclusionsDynamic changes in HER2-peptide-specific autoantibodies during NAC, rather than static titers alone, may provide informative biomarkers for predicting clinical response. Serum HER2 levels were not significantly associated with pCR, suggesting that autoantibody profiling may capture response-related biology not reflected by antigen levels alone. These findings provide proof-of-concept evidence that minimally invasive, longitudinal profiling of peptide-specific autoantibodies could complement established response-assessment modalities, such as imaging or molecular assays. However, these results are exploratory and require validation in larger, independent cohorts before clinical application.Trial registrationUMIN000007576 (Registration date: March 26, 2012).Supplementary InformationThe online version contains supplementary material available at 10.1186/s13058-026-02259-y.Keywords: Breast cancer, HER-2, Autoantibody, Neoadjuvant chemotherapy, Pathological complete response, Humoral immune response, HER2-peptide, Machine learning, Elastic net regression Background Anti-HER2 therapy is the standard care for patients with HER2-positive breast cancer. Originally developed for advanced or recurrent diseases, these targeted agents have been successfully incorporated into perioperative treatment strategies [1]. Neoadjuvant chemotherapy (NAC) administered before surgery aims to reduce tumor burden and increase the feasibility of breast-conserving surgery. In HER2-positive patients, NAC leads to substantial tumor shrinkage and results a pathologic complete response (pCR) in approximately 40–50% patients [2, 3]. Given that pCR is a well-established prognostic indicator [4, 5], and the absence of pCR informs the selection of subsequent adjuvant therapies [6], NAC has become a widely accepted standard approach for this patient population. Nevertheless, accurate identification of patients who achieve pCR after NAC remains a significant clinical challenge, despite several known potential predictive parameters [7–10]. Recently, the HER2DX genomic test, which integrates a 27-gene expression panel with a clinical feature-based classifier, has shown promising performance in predicting pCR in early stage HER2-positive breast cancer [9, 10]. In addition, serological approaches that assess autoantibodies against self-proteins may provide complementary information by capturing real-time, treatment-induced immune dynamics, thereby offering insights beyond static tumor genomic features [11]. Nevertheless, clinically reliable biomarkers for predicting a pCR remain unavailable. In addition to its role as a therapeutic target for monoclonal antibodies and tyrosine kinase inhibitors, HER2 has garnered interest as a tumor-associated antigen capable of inducing cellular and humoral immune responses [12–15]. Azuma et al. identified HER2-derived peptides that elicit specific cellular and humoral immune responses, supporting the feasibility of peptide-based immunotherapeutic strategies [16]. Several studies have also highlighted the clinical relevance of HER2-specific autoantibodies in breast cancer [17–20]. Moreover, we previously demonstrated that plasma IgG titers against EGFR-derived peptides correlate with the clinical efficacy of gefitinib in patients with non-small cell lung cancer, highlighting the potential of peptide-specific antibody responses as predictive biomarkers [21]. Based on these findings, in this study, we aimed to conduct a comprehensive analysis of the HER2-specific humoral immune responses in serum samples from patients with HER2-positive breast cancer receiving NAC with anti-HER2 agents. Unlike previous studies that used the full-length HER2 protein or the extracellular domain (ECD) [17–20], our approach systematically evaluated specific humoral responses against a broad panel of HER2-derived linear peptides, allowing fine mapping of humoral immunogenicity. We identified a combination of immunogenic HER2-derived peptides that was significantly associated with pCR, which is a well-established surrogate endpoint for NAC efficacy [2–6]. These results suggest the potential utility of HER2-peptide-specific antibody responses as novel biomarkers for predicting treatment response in this patient population. Methods Patients, treatments, and sample collection This study was approved by the Kanagawa Cancer Center Clinical Ethics Review Committee (28 Epidemic-56) and was conducted in accordance with the Declaration of Helsinki and relevant ethical guidelines for clinical and epidemiological studies. Among the 212 patients enrolled in the JBCRG-16 (Neo-Lath) trial (UMIN000007576), which evaluated the pCR rate following preoperative chemotherapy, including anti-HER2 therapy for HER2-positive breast cancer [22, 23], 112 (52.8%) provided written informed consent to participate in an ancillary study involving serum analysis. Institutional review board approval was obtained from each participating site for the original trial and follow-up study, including the National Hospital Organization Osaka National Hospital (approval no. 2011-0017 on January 17, 2012/approval no. 2014 − 1015 on June 17, 2014). Informed consent was obtained from all patients at the beginning of the JBCRG-16 (Neo-Lath) trial. Serum samples were collected before NAC (pre-NAC, n = 112) and after NAC but before surgery (post-NAC, n = 102) to measure serum IgG titers against HER2-derived peptides. Serum HER2 levels were measured using a chemiluminescent immunoassay (CLIA) method at specialized laboratories designated by each participating institution using a subset of samples collected before NAC (n = 66), after NAC (n = 65), and at both time points (n = 55). The JBCRG-16 (Neo-Lath) trial evaluated five treatment arms defined by hormone receptor status and regimen, as shown in Supplementary Fig. S1. Patients with ER-negative disease received either (A) lapatinib plus trastuzumab for six weeks followed by the same doublet combined with weekly paclitaxel for 12 weeks, or (B) an 18-week course of lapatinib plus trastuzumab followed by the same doublet combined with weekly paclitaxel for 12 weeks. Patients with ER-positive disease received one of the following regimens: (C) lapatinib plus trastuzumab for six weeks followed by the same doublet combined with weekly paclitaxel for 12 weeks, without endocrine therapy; (D) the same regimen with concomitant endocrine therapy throughout the chemotherapy phase; or (E) an 18-week course of lapatinib plus trastuzumab followed by the same doublet combined with weekly paclitaxel for 12 weeks, with concomitant endocrine therapy throughout the chemotherapy phase. Thus, Groups A, C, and D received lapatinib and trastuzumab for six weeks, whereas Groups